NO311867B1 - Fremgangsmåte for kondisjonering av vannopplöselige stoffer - Google Patents
Fremgangsmåte for kondisjonering av vannopplöselige stoffer Download PDFInfo
- Publication number
- NO311867B1 NO311867B1 NO19933575A NO933575A NO311867B1 NO 311867 B1 NO311867 B1 NO 311867B1 NO 19933575 A NO19933575 A NO 19933575A NO 933575 A NO933575 A NO 933575A NO 311867 B1 NO311867 B1 NO 311867B1
- Authority
- NO
- Norway
- Prior art keywords
- substances
- solvent
- inert gas
- micronized
- conditioning
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 11
- 239000000126 substance Substances 0.000 title claims 9
- 230000003750 conditioning effect Effects 0.000 title claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- 239000011261 inert gas Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000003266 anti-allergic effect Effects 0.000 claims 2
- 230000001088 anti-asthma Effects 0.000 claims 2
- 239000000924 antiasthmatic agent Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- HWAXMFYECKQLDX-UHFFFAOYSA-N 5-[[(4-chlorobenzoyl)amino]methyl]thiophene-2-sulfonyl chloride Chemical compound C1=CC(Cl)=CC=C1C(=O)NCC1=CC=C(S(Cl)(=O)=O)S1 HWAXMFYECKQLDX-UHFFFAOYSA-N 0.000 claims 1
- AWRLZJJDHWCYKN-UHFFFAOYSA-N 5-bromo-2-ethoxy-3-nitropyridine Chemical compound CCOC1=NC=C(Br)C=C1[N+]([O-])=O AWRLZJJDHWCYKN-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 229960003416 bambuterol hydrochloride Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 229960003237 betaine Drugs 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229960001037 fenoterol hydrobromide Drugs 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000013557 residual solvent Substances 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960005105 terbutaline sulfate Drugs 0.000 claims 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims 1
- 229960000351 terfenadine Drugs 0.000 claims 1
- 239000012808 vapor phase Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
- Detergent Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Treating Waste Gases (AREA)
- Hydrogenated Pyridines (AREA)
- Paper (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Cephalosporin Compounds (AREA)
- General Preparation And Processing Of Foods (AREA)
Claims (10)
1.
Frremgangsmåte for tilveiebringelse av vannoppløselige, mikroniserte stoffer med en partikkelstørrelse på mindre enn 100 um, fortrinnsvis mindre enn 10 um, som kan fremstilles, lagres og anvendes under opprettholdelse av de aereodynamiske egenskapene som er nødvendig for inhalering av slike stoffer, karakterisert veda) redusering, om nødvendig, av det resterende vannet fra det mikroniserte stoffet ved tørking eventuelt ved en forhøyet temperatur og/eller vakuum, b) kondisjonering av nevnte tørkede, mikroniserte stoffer med et oppløsningsmiddel, og c) fjerning av resterende oppløsningsmiddel ved lagring på et tørt sted slik som vakuum eller ved spyling med en inert gass.
2.
Fremgangsmåte ifølge krav 1, karakterisert ved at oppløsningsmidlet som benyttes i kondisjoneirngstrinnet b) er etanol, aceton eller lignende, fortrinnsnvis i dampfasen.
3.
Fremgangsmåte ifølge krav 2, karakterisert ved at oppløsningsmidlet som benyttes i trinn b) er etanol.
4.
Fremgangsmåte ifølge hvilket som helst av kravene 1-3, karakterisert ved at kondisjoneringstrinnet b) utføres i en inert gass inneholdende oppløsningsmiddeldamp.
5.
Fremgangsmåte ifølge hvilket som helst av kravene 1-4, karakterisert ved at den inerte gassen som benyttes i trinn c) og eventuelt i trinn b) er nitrogen.
6.
Fremgangsmåte ifølge hvilket som helst av kravene 1-5, karakterisert ved at stoffene er additiver, slik som karbohydrater og aminosyrer.
7.
Fremgangsmåte ifølge krav 6, karakterisert ved at karbohydratene som benyttes er laktose, glykose, fruktose, galaktose, trehalose, sukrose, maltose, xylitol, mannitol, myoinositol eller lignende og at aminosyrene som benyttes er alanin, betain eller lignende.
8.
Fremgangsmåte ifølge hvilket som helst av kravene 1-6, karakterisert ved at stoffene er legemidler.
9.
Fremgangsmåte ifølge krav 8, karakterisert ved at legemidlene er antiastmatiske eller antiallergiske stoffer.
10.
Fremgangsmåte ifølge krav 8, karakterisert ved at. nevnte antiastmatiske eller antiallergiske stoffer velges fra terbutalinsulfat, salbutamolsulfat, fenoterolhydrobromid, bambuterolhydroklorid, terfenadin og dinatriumkromoglykat.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9101090A SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Process for conditioning of water-soluble substances |
| PCT/SE1992/000186 WO1992018110A1 (en) | 1991-04-11 | 1992-03-24 | Process for conditioning of water-soluble substances |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO933575D0 NO933575D0 (no) | 1993-10-06 |
| NO933575L NO933575L (no) | 1993-10-06 |
| NO311867B1 true NO311867B1 (no) | 2002-02-11 |
Family
ID=20382434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19933575A NO311867B1 (no) | 1991-04-11 | 1993-10-06 | Fremgangsmåte for kondisjonering av vannopplöselige stoffer |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5562923A (no) |
| EP (3) | EP0508969A1 (no) |
| JP (2) | JP3400999B2 (no) |
| KR (1) | KR100216384B1 (no) |
| AT (2) | ATE208613T1 (no) |
| AU (1) | AU662519B2 (no) |
| BG (1) | BG61474B1 (no) |
| CA (1) | CA2106975C (no) |
| CZ (1) | CZ286936B6 (no) |
| DE (2) | DE69232207T2 (no) |
| DK (2) | DK0580648T3 (no) |
| EE (1) | EE02970B1 (no) |
| ES (2) | ES2086733T3 (no) |
| FI (1) | FI105388B (no) |
| GR (1) | GR3020602T3 (no) |
| HK (1) | HK52497A (no) |
| HU (1) | HU211116B (no) |
| IE (1) | IE921144A1 (no) |
| IS (1) | IS3834A (no) |
| NO (1) | NO311867B1 (no) |
| PL (1) | PL168232B1 (no) |
| PT (1) | PT680752E (no) |
| RO (1) | RO115779B1 (no) |
| RU (1) | RU2112507C1 (no) |
| SE (1) | SE9101090D0 (no) |
| SG (1) | SG43180A1 (no) |
| SK (1) | SK280310B6 (no) |
| WO (1) | WO1992018110A1 (no) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| US5980949A (en) * | 1994-10-03 | 1999-11-09 | Astra Aktiebolag | Formulation for inhalation |
| US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| KR100405116B1 (ko) * | 1995-02-28 | 2004-02-05 | 아벤티스 파마슈티칼스 인크. | 피페리디노알칸올화합물에대한약제학적조성물 |
| US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| GB9526392D0 (en) * | 1995-12-22 | 1996-02-21 | Glaxo Group Ltd | Medicaments |
| SE9700133D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| SE9700135D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| ID24472A (id) * | 1997-03-20 | 2000-07-20 | Schering Corp | Pembuatan aglomerat bubuk |
| US6495167B2 (en) | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
| US6503537B2 (en) | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
| TR200000517T2 (tr) * | 1997-08-26 | 2000-08-21 | Hoechst Marion Roussel, Inc. | Piperidinoalkanol-Konjesyon azaltıcıdan oluşan kombinasyona yönelik farmasötik kompozisyon. |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| EA002562B1 (ru) * | 1997-09-29 | 2002-06-27 | Инхэл Терапьютик Системз, Инк. | Перфорированные микрочастицы и способ их использования |
| FI105074B (fi) * | 1997-12-31 | 2000-06-15 | Leiras Oy | Farmaseuttisen formulaation valmistusmenetelmä |
| US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
| GB9826286D0 (en) * | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| GB9826284D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| US8722668B2 (en) * | 1998-12-23 | 2014-05-13 | Daryl W. Hochman | Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders |
| US6623760B1 (en) | 1999-01-28 | 2003-09-23 | Schering Corporation | Method of preparing particles for agglomeration |
| AR022695A1 (es) * | 1999-01-28 | 2002-09-04 | Schering Corp | PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| US7309707B2 (en) | 2002-03-20 | 2007-12-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
| US7244415B2 (en) | 2002-03-28 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations of an anhydrate |
| US20040028746A1 (en) * | 2002-08-06 | 2004-02-12 | Sonke Svenson | Crystalline drug particles prepared using a controlled precipitation (recrystallization) process |
| GB0228826D0 (en) * | 2002-12-11 | 2003-01-15 | Okpala Joseph | Hair technology in creating particles with improved delivery capabilities |
| ES2233227T1 (es) * | 2003-03-26 | 2005-06-16 | Teva Pharmaceutical Industries Ltd. | Procedimiento para la preparacion de ingredientes farmaceuticos activos con un area superficial especifica. |
| PT1844765E (pt) * | 2003-06-13 | 2015-05-20 | Skendi Finance Ltd | Formulação de estradiol-progesterona de libertação lenta |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| BRPI0415579A (pt) * | 2003-10-17 | 2007-01-02 | Du Pont | estrutura em multicamadas, embalagem e processo |
| EP1711166A1 (en) | 2004-02-03 | 2006-10-18 | Chemagis Ltd. | Stable amorphous forms of montelukast sodium |
| DE102004048389A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa |
| DE102004048390A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff |
| US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
| KR20100099281A (ko) * | 2007-12-13 | 2010-09-10 | 노파르티스 아게 | 유기 화합물 |
| GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| WO2011110852A1 (en) | 2010-03-10 | 2011-09-15 | Astrazeneca Ab | Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide |
| CN103814015A (zh) | 2011-06-29 | 2014-05-21 | 阿斯利康(瑞典)有限公司 | 用于治疗糖皮质激素受体介导的障碍的吲唑基酰胺衍生物的结晶形式 |
| WO2014144894A1 (en) * | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
| WO2021219230A1 (en) | 2020-04-30 | 2021-11-04 | Paolo Fiorina | Antiviral treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3978192A (en) * | 1971-09-23 | 1976-08-31 | Sussman Martin V | Method of drawing fibers using a microterraced drawing surface |
| US4405598A (en) * | 1976-01-30 | 1983-09-20 | Fisons, Limited | Composition for treating asthma |
| KR890000664B1 (ko) * | 1981-10-19 | 1989-03-22 | 바리 안소니 뉴우샘 | 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법 |
| US4476130A (en) * | 1982-09-09 | 1984-10-09 | Riker Laboratories, Inc. | 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity |
| EP0258258B1 (de) * | 1985-06-21 | 1989-03-29 | Gergely, Gerhard, Dr. | Verfahren und vorrichtung zur behandlung von prozessgut, sowie mit hilfe des verfahrens und/oder der vorrichtung hergestelltes reaktivprodukt |
| IT1204826B (it) * | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| CA2030581C (en) * | 1989-11-24 | 2000-06-27 | Gunther Atzl | Pancreatin preparations |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
-
1991
- 1991-04-11 SE SE9101090A patent/SE9101090D0/xx unknown
-
1992
- 1992-03-24 HU HU9302870A patent/HU211116B/hu unknown
- 1992-03-24 CZ CZ19932116A patent/CZ286936B6/cs not_active IP Right Cessation
- 1992-03-24 DE DE69232207T patent/DE69232207T2/de not_active Expired - Lifetime
- 1992-03-24 SK SK1088-93A patent/SK280310B6/sk not_active IP Right Cessation
- 1992-03-24 AU AU15347/92A patent/AU662519B2/en not_active Expired
- 1992-03-24 PL PL92301008A patent/PL168232B1/pl unknown
- 1992-03-24 CA CA002106975A patent/CA2106975C/en not_active Expired - Lifetime
- 1992-03-24 AT AT95111178T patent/ATE208613T1/de active
- 1992-03-24 SG SG1996004975A patent/SG43180A1/en unknown
- 1992-03-24 ES ES92907877T patent/ES2086733T3/es not_active Expired - Lifetime
- 1992-03-24 PT PT95111178T patent/PT680752E/pt unknown
- 1992-03-24 RO RO93-01336A patent/RO115779B1/ro unknown
- 1992-03-24 EP EP92850062A patent/EP0508969A1/en active Pending
- 1992-03-24 DE DE69210601T patent/DE69210601T2/de not_active Expired - Lifetime
- 1992-03-24 JP JP50719592A patent/JP3400999B2/ja not_active Expired - Lifetime
- 1992-03-24 WO PCT/SE1992/000186 patent/WO1992018110A1/en active IP Right Grant
- 1992-03-24 ES ES95111178T patent/ES2168322T3/es not_active Expired - Lifetime
- 1992-03-24 RU RU93058260A patent/RU2112507C1/ru active
- 1992-03-24 EP EP95111178A patent/EP0680752B1/en not_active Expired - Lifetime
- 1992-03-24 DK DK92907877.2T patent/DK0580648T3/da active
- 1992-03-24 DK DK95111178T patent/DK0680752T3/da active
- 1992-03-24 EP EP92907877A patent/EP0580648B1/en not_active Expired - Lifetime
- 1992-03-24 KR KR1019930703065A patent/KR100216384B1/ko not_active IP Right Cessation
- 1992-03-24 AT AT92907877T patent/ATE137671T1/de active
- 1992-04-10 IS IS3834A patent/IS3834A/is unknown
- 1992-04-10 IE IE114492A patent/IE921144A1/en not_active IP Right Cessation
-
1993
- 1993-10-06 NO NO19933575A patent/NO311867B1/no not_active IP Right Cessation
- 1993-10-08 FI FI934429A patent/FI105388B/fi not_active IP Right Cessation
- 1993-10-08 BG BG98147A patent/BG61474B1/bg unknown
-
1994
- 1994-11-17 EE EE9400417A patent/EE02970B1/xx unknown
-
1995
- 1995-06-07 US US08/479,494 patent/US5562923A/en not_active Expired - Lifetime
-
1996
- 1996-07-23 GR GR960401961T patent/GR3020602T3/el unknown
-
1997
- 1997-04-24 HK HK52497A patent/HK52497A/xx not_active IP Right Cessation
-
2002
- 2002-11-29 JP JP2002347368A patent/JP2003155228A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO311867B1 (no) | Fremgangsmåte for kondisjonering av vannopplöselige stoffer | |
| RU93058260A (ru) | Способ получения водорастворимых микронизированных веществ | |
| CA2022104C (en) | Supercritical fluid and near critical gas extraction of organic solvents from formed articles | |
| KR0167122B1 (ko) | 저농약 함량의 식물 활성 성분 농축물의 제조 방법 | |
| Smith et al. | Supercritical fluid extraction and gas chromatographic determination of the sesquiterpene lactone parthenolide in the medicinal herb feverfew (Tanacetum parthenium) | |
| JPH09508695A (ja) | 溶液から材料を乾燥する方法 | |
| NO180801C (no) | Fremgangsmåte til fremstilling av et frysetörket preparat | |
| RU93004547A (ru) | Фармацевтический состав на основе tanacetum partheniom, способ его получения и лекарственное средство на его основе | |
| KR910000709A (ko) | 온단세트론 염산염 이수화물 결정의 입도 감소법 | |
| Smolarz | Comparative study on the free flavonoid aglycones in herbs of different species of Polygonum L | |
| IE36411L (en) | Tobacco aroma substances. | |
| RU2006126051A (ru) | Способы получения партии активного фармацевтического ингредиента, контейнер, содержащий криогранулы аллергенного продукта, и криогранула аллергенного продукта | |
| KR960000427B1 (ko) | 경질 피복 물질에 캡슐화시키기에 특히 적합한 약제 및 이의 제조 방법 | |
| ATE86477T1 (de) | Galenische form eines trockenextraktes von pflanzen. | |
| ES2061713T3 (es) | Nuevas formas galenicas de corticoides para administracion por via per- y sublingual y su procedimiento de preparacion. | |
| Kauffman et al. | Improved apparatus for continuous column chromatography | |
| CN108782885B (zh) | 一种保留药效活性成分的三叶青茶加工方法 | |
| EP0932409B1 (en) | A method for producing an extract from valeriana officinalis containing high levels of valerenic acid | |
| JPS57118790A (en) | Freeze-dried substance containing beta-d-galactosidase | |
| KR940002798B1 (ko) | 플라본배당체의 추출방법과 그 장치 | |
| KR960000244A (ko) | 필리오스티그마 톤닌지의 추출물, 그 이용방법 및 그것을 포함하는 조성물 | |
| RU99117036A (ru) | Способ получения сухой комбинированной сибиреязвенной вакцины | |
| JPH04255799A (ja) | 揮発性有効成分の抽出方法 | |
| LEE et al. | An aerodynamic analysis and the subsequent motion of external store | |
| US20210290733A1 (en) | Injectable micronized human insulin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |